New research is raising fresh questions about testosterone therapy in postmenopausal women, after a large observational study found higher rates of heart attack, stroke and other cardiovascular events among women who used the treatment. Experts say the numbers deserve attention, especially in older women, but they also stress that the findings do not prove the therapy caused the problems.
Check these points:
- Testosterone therapy and cardiovascular risk
- Postmenopausal women and sexual health
- Differences in event rates between treatment groups
- Limits of observational research
- Need for careful patient screening and monitoring
The study looked at more than 6,000 postmenopausal women age 45 and older and compared those who received testosterone with those who did not. Women with prior cardiovascular disease were left out, making the comparison narrower but still important for spotting possible safety concerns.
Researchers reported that 3.8% of women receiving testosterone had a first cardiovascular event, while the figure was 0.5% in women who were not treated. Those events included heart attack, stroke, heart failure and similar problems, which is a pretty stark gap on paper.
Testosterone is produced by the ovaries and adrenal glands and plays a role in sexual desire, along with muscle and bone health, mood and cognition. For many women, interest in the hormone has grown because of hopes that it may help with libido, arousal and overall intimacy after menopause.
That promise is part of why the new findings matter. Sexual health is a real quality-of-life issue, and women dealing with low desire or discomfort often want options that feel practical, not dismissive or vague.
Still, experts say the decision to use testosterone should never be made in a vacuum. Heart history, blood pressure, cholesterol, diabetes, medications and family background all need to be part of the conversation before treatment starts.
Specialists also say the raw numbers need context. A difference between 3.8% and 0.5% is not something to shrug off, but it also does not automatically mean the hormone was the direct cause of the events.
That caution comes down to the type of study involved. Because the research was observational, it tracked women who were already using testosterone rather than assigning treatment in a controlled trial.
That leaves room for hidden differences between the groups. Women who received testosterone may have been older, had higher blood pressure, more diabetes, worse cholesterol or other health issues that pushed their risk higher from the start.
In practical terms, the takeaway is not panic, but restraint. Testosterone may still help selected postmenopausal women, but it should be used thoughtfully, with clear reasons for prescribing it and a close eye on how the body responds.
Careful dosing and regular follow-up matter a lot here. Symptoms, lab work and general health should all stay under review, especially when the goal is to improve desire without opening the door to avoidable risk.
The study is already being viewed as an important signal rather than a final verdict. That distinction matters because hormone therapy often lives in a gray zone, where potential benefits are real, but so are the tradeoffs.
Women considering testosterone deserve direct answers, not hand-waving. The smartest approach is to match treatment to the person, not the trend, and make sure the conversation includes both sexual health and heart health from the start.
